The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN Conference

Vaccine

Volumn 26, Issue 43, 2008, Pages 5435-5440

  Garland, S ^a,b   Park, S N ^c   Ngan, H Y S ^d   Frazer, I ^e   Tay, E H ^f   Chen, C J ^g   Bhatla, N ^h   Pitts, M ⁱ   Shin, H R ^j,k   Konno, R ^l   Smith, J ^m   Pagliusi, S ⁿ   Park, J S ^o  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Korea Food and Drug Administration   (South Korea)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^g GENOMICS RESEARCH CENTER   (Taiwan)

^h ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

ⁱ LA TROBE UNIVERSITY   (Australia)

^j National Cancer Center   (South Korea)

^k INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^l JICHI MEDICAL UNIVERSITY   (Japan)

^m The University of North Carolina at Chapel Hill   (United States)

ⁿ WORLD HEALTH ORGANIZATION   (Switzerland)

^o The Catholic University of Korea   (South Korea)

more..

Author keywords

Cervical cancer prevention; Cervical screening; HPV vaccines; Public health education

Indexed keywords

WART VIRUS VACCINE;

ASIA; CANCER CONTROL; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; CONFERENCE PAPER; EDUCATION PROGRAM; GENERAL PRACTITIONER; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PATIENT EDUCATION; PEDIATRICIAN; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; ASIA; CHILD; FEMALE; HEALTH EDUCATION; HUMANS; MASS IMMUNIZATION; PAPILLOMAVIRUS VACCINES; SCHOOLS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 52449111258     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.077     Document Type: Conference Paper

References (14)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. IARC Monograph Working Group. Carcinogenicity of human papillomaviruses. Lancet 2005;6:204 and IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses, vol. 90. Lyon, France; 2007.
3. Suárez E, Smith JS, Bosch X, Nieminen P, Chen CJ, Torvinen S, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008 (Suppl.), in press.
4. Bhatla N., Mukhopadhyay A., Kriplani A., Pandey R.M., Gravitt P.E., Shah K.V., et al. Evaluation of adjunctive tests for cervical cancer screening in low resource settings. Indian J Cancer 44 2 (2007) 51-55
5. Tay E.H., Garland S., Tang G., Nolan T., Huang L.M., Orloski L., et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Int J Gynaecol Obstet (2008) In press
6. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al., HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
7. Bray F., Loos A.H., McCarron P., Weiderpass E., Arbyn M., Møller H., et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 14 3 (2005) 677-686
8. Chien Y.C., Jan C.F., Kuo H.S., and Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in 20 years after it was launched. Epidemiol Rev 28 (2006) 126-135
9. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against the human papillomavirus to prevent cervical, vulvar and vaginal disease. N Engl J Med 356 19 (2007) 1928-1943
10. Skinner R.S., Garland S.M., Stanley M.A., Pitts M., and Quinn M.A. Human Papillomavirus vaccination for the prevention of cervical neoplasia; is it appropriate to vaccinate women older than 26?. Med J A 188 4 (2008) 238-242
11. Brabin L., Roberts S.A., Stretch R., Baxter D., Chambers G., Kitchener H., et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. Br Med J 336 (2008) 1056-1058
12. Poynten IM, Jin FY, Prestage G, Mao l, Kippax S, Kaldor J, et al. Non-occupational post exposure prophylaxis against HIV (NPEP) and subsequent HIV infection in homosexual men: final data from the HIM cohort ASHM Conference, September 2008, Perth.
13. Shin H.R., Franceschi S., Vaccarella S., Roh J.W., Ju Y.H., Oh J.K., et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 190 3 (2004) 468-476
14. Clifford G.M., Shin H.R., Oh J.K., Waterboer T., Ju Y.H., Vaccarella S., et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 16 9 (2007) 1874-1879